

Fig. S1 (supplementary data): two-way ANOVA of the morphometric measurements.

¹Statistical limit established in $P < 0.05$. Statistical significances marked in bold.

Measuremen t	Comparison type	F value	Significance ₁
SL	Treatment	8.920	0.558
	Time	1477.91 3	0.000
	Treatment*Time	3.362	0.018
TPM-MCH	Treatment	20.890	0.000
	Time	355.305	0.000
	Treatment*Time	34.611	0.000
MCH-ADF	Treatment	32.180	0.000
	Time	393.796	0.000
	Treatment*Time	77.294	0.000
ADF-PDF	Treatment	38.159	0.000
	Time	299.923	0.000
	Treatment*Time	63.812	0.000
PDF-PAF	Treatment	1.059	0.003

	Time	523.070	0.000
	Treatment*Time	1.394	0.000

Measuremen t	Comparison type	F value	Significance ₁
PAF-AAF	Treatment	11.943	0.006
	Time	266.578	0.000
	Treatment*Time	43.167	0.000
AAF-PF	Treatment	2.833	0.001
	Time	795.336	0.000
	Treatment*Time	4.289	0.073
PF-OP	Treatment	6.653	0.023
	Time	205.781	0.000
	Treatment*Time	6.334	0.107
OP-TPM	Treatment	5.084	0.000
	Time	203.462	0.000
	Treatment*Time	1.799	0.000
OP-DPF	Treatment	16.989	0.020
	Time	347.792	0.000
	Treatment*Time	8.926	0.000
ED	Treatment	2.894	0.330

	Time	2169.55 6	0.000
	Treatment*Time	2.008	0.519

Measuremen t	Comparison type	F value	Significance ₁
MHC-OP	Treatment	3.421	0.000
	Time	646.802	0.000
	Treatment*Time	7.881	0.000
MHC-PF	Treatment	5.498	0.111
	Time	778.222	0.000
	Treatment*Time	6.206	0.031
MHC-AAF	Treatment	4.955	0.035
	Time	1120.46 8	0.000
	Treatment*Time	12.757	0.002
ADF-PF	Treatment	1.852	0.007
	Time	1345.60 9	0.000
	Treatment*Time	6.422	0.122
ADF-AAF	Treatment	20.758	0.000

	Time	664.408	0.000
	Treatment*Time	63.790	0.000
ADF-PAF	Treatment	40.100	0.000
	Time	496.351	0.000
	Treatment*Time	47.629	0.000